A Highly Biocompatible Polyoxotungstate with Fenton-like Reaction Activity for Potent Chemodynamic Therapy of Tumors.

Integrating Fenton chemistry and nanomedicine into cancer therapy has significantly promoted the development of chemodynamic therapy (CDT). Nanoscale polyoxometalates (POMs), with their reversible redox properties, exhibit promising potential in developing outstanding CDT drugs by exploring their Fenton-like catalytic reactivity in tumor environments. However, such research is still in its infancy due to the challenges of acquiring POMs that are both easily prepared and possess ideal therapeutic effects, physiological solubility, biocompatibility and safety.

Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1.

Recent progress in the development of small molecular skeleton-derived polo-like kinase (PLK1) catalytic domain (K) inhibitors has led to the synthesis of multiple ligands with high binding affinity. However, few systematic analyses have been conducted to identify key PLK1-PBD domain and characterize their interactions with potent PLK1 inhibitors. Therefore, we designed a series of PLK1-PBD inhibitors with an in silico scaffold modification strategy.